Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 878Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Stomach Neoplasms 512Esophageal Neoplasms 312Rectal Neoplasms 280Colonic Neoplasms 254Breast Neoplasms 203Neoplasms 201Liver Neoplasms 187Lung Neoplasms 174Carcinoma, Non-Small-Cell Lung 174Cholangiocarcinoma 153Ovarian Neoplasms 141Neoplasm Metastasis 135Gastrointestinal Neoplasms 133Esophageal Squamous Cell Carcinoma 130Melanoma 103Prostatic Neoplasms 98Biliary Tract Neoplasms 95Endometrial Neoplasms 83Uterine Cervical Neoplasms 79Head and Neck Neoplasms 72Squamous Cell Carcinoma of Head and Neck 69Carcinoma, Renal Cell 58Sarcoma 54Adenocarcinoma Of Esophagus 54Urinary Bladder Neoplasms 53Anus Neoplasms 52Triple Negative Breast Neoplasms 48

Interventions

durvalumab 1Surgical Procedures, Operative 1Specimen Handling 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cisplatin 1Capecitabine 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Resectable Intrahepatic Cholangiocarcinoma × Gastrointestinal × Clear all
NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

National Cancer Institute (NCI)

Phase 2 Recruiting
27 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT05265208 2025-08-06

SIROCHO

Center Eugene Marquis

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡